AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 182 min read$RDNT

Wesdorp Cornelis sold $276K of RDNT

Wesdorp Cornelis (Pres & CEO, Digital Health) sold 4,750 shares of RadNet, Inc. (RDNT) at $58.11 ($0.28M total) on 2026-06-16.

Original reporting
SEC EDGAR · Wesdorp Cornelis
Published Jun 18, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RDNT
Neutral
high confidence
Mentioned
$RDNT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDNTNeutralLow
01

Why it matters

This provides a concrete datapoint on CEO selling size, price, and post-transaction holdings, but it does not introduce new operational or financial guidance.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a fundamental repricing on its own.

03

What to watch

Insider sales are common and often non-informational; traders should compare with prior insider activity and whether other executives/large holders are also selling or buying around the same period.

Relevance 4/10Novelty 5/10Timing: Filed after-hours on 2026-06-18; reflects sale executed 2026-06-16.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for RadNet, Inc. (RDNT).

Company-level read

Ticker impact

$RDNTNeutralHigh confidence
Context

RadNet CEO Wesdorp Cornelis filed a Form 4 selling 4,750 shares at $58.11 on 2026-06-16 for ~$276K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is a disclosed sale with no 10b5-1 plan and no accompanying fundamental catalyst (no guidance, deal, or regulatory action).

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan could be misread as bearish; the sale may be for diversification/taxes rather than a view on fundamentals.

Key entities

  • US-listed issuer
    RadNet, Inc.

    Subject of the Form 4 insider sale by its CEO.

  • Insider
    Wesdorp Cornelis

    President & CEO, Digital Health; reported an open-market sale of RDNT shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RDNT insider trading history →

Related articles

OCT 27
$RDNTHighAI 8/10

Truist reiterates Buy on RadNet stock after ONRAD acquisition

Truist Securities reiterated a Buy rating and $94 price target on RadNet (RDNT) after its $700M acquisition of ONRAD. The deal includes cash, shares, and an earnout. RadNet's stock trades at $73.77, with analysts citing growth potential. The company reported strong Q2 2026 results, raising guidance and prompting price target increases from multiple analysts.

investing.com2 min
OCT 27
HighAI 9/10

RadNet acquires ONRAD in $355m deal to broaden radiology provision

RadNet agreed to acquire ONRAD for $355m ($350m cash, $5m shares) with a potential $210m earnout. The deal, expected to close in early 2027, aims to expand RadNet's radiology services and address staffing shortages. RadNet plans to integrate ONRAD's teleradiology and staffing services with its AI-based solutions to improve efficiency and patient care. Jefferies analysts called it a 'sound transaction.'

medicaldevice-network.com2 min
SEP 16
$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

yahoo.com3 min
SEP 4
$RDNTMed

RadNet (RDNT) Posts Record Revenue But Profit Growth Lags

RadNet (RDNT) reported Q2 2026 revenue of $622.7M, up 25% YoY, and raised full-year guidance. Profit growth lagged, with net income falling to $7.5M from $14.5M YoY. Digital Health revenue grew 56.5%, but its EBITDA dropped 27.2%. Hedge fund ownership declined, while short interest remains high at 14.56%.

insidermonkey.com3 min